



ImpediMed Limited
Suite 31C, 12-18 Tryon Rd
Lindfield NSW 2070
Australia

E: investorrelations@impedimed.com
W : impedimed.com

12 May 2026

Companies Announcements Office
Australian Securities Exchange

Letters to Shareholders

ImpediMed Limited (ASX:IPD) (ImpediMed or the Company) advises that further to the announcement of the opening of the Share Purchase Plan, letters to eligible and ineligible shareholders are attached. These letters are being dispatched to ImpediMed shareholders today.

Approved for release by the Board of ImpediMed Limited.

For more information, contact Leanne Ralph, Company Secretary, at leanne.ralph@bellev.com.au

For personal use only

12 May 2026

Share Purchase Plan Letter to Eligible Shareholders

Dear Shareholder

Invitation to participate in Share Purchase Plan

On behalf of the Board of ImpediMed Limited (ASX: IPD) (**ImpediMed** or the **Company**), I am pleased to offer you the opportunity to participate in the ImpediMed share purchase plan (**SPP**) which was announced on 4 May 2026. The SPP provides you with an opportunity to acquire up to A\$100,000 worth of ImpediMed's ordinary shares (**SPP Shares**) at a price which is equal to the lower of \$0.01 per SPP Share or a 2.5% discount to the VWAP of Company's shares traded on the ASX during the 5 trading days up to the closing date of the SPP (**Issue Price**) to raise up to approximately \$2.0 million.

Each Eligible Shareholder will also receive one Attaching Option (exercise price of \$0.01 and expiry date of 31 March 2027) and one Follow-On Option (exercise price of \$0.015 and expiry date of 31 December 2027) for every SPP Share subscribed.

Subject to the ASX conditions for quotation of securities, the Company will apply for the quotation of these Options and in the event that the Options are not granted quotation, the Company will issue those Options as unquoted options.

The Company reserves the right to accept oversubscriptions up to a total of 100 million additional SPP Shares under the SPP.

The SPP is part of a broader capital raising being undertaken by ImpediMed. As announced to ASX on 4 May 2026, the Company is undertaking the Placement and SPP to raise a total of approximately \$15.2 million in order to strengthen its balance sheet by partially repaying the SWK Facility and providing additional working capital to support its ongoing operations.

The first tranche of the Placement has raised \$3.0 million (before costs). Completion of Tranche 2 and the SPP are each conditional on shareholder approval, which will be sought at an extraordinary general meeting scheduled on 11 June 2026 (**EGM**).

If Shareholders do not approve either the issue of securities under the Tranche 2 or the issue of securities under the SPP, Tranche 2 of the placement and the SPP will not proceed, and the Company will not raise any further funds.

Prospectus

The SPP is subject to the terms and conditions set out in the prospectus. A copy of the prospectus was lodged with ASX on 4 May 2026 (**Prospectus**). The Company encourages you to carefully read the Prospectus in full before making your investment decision, noting that you will be bound by the terms and conditions in the Prospectus if you choose to participate.

A copy of the Prospectus, along with instructions on how to apply for the SPP and submit your payment, is available online at events.miraqle.com/ipd-spp.

About the SPP

The SPP Offer will open on 12 May 2026 and close on 5 June 2026, see the Indicative Timetable below for further information on the important dates of the SPP Offer. Pursuant to the SPP Offer, Eligible Shareholders may apply for a maximum of \$100,000 worth of SPP Shares, where the amount applied for results in a fraction of a Share, the number of SPP Shares issued will be rounded down to the nearest whole number. There is no minimum application amount. All SPP Shares issued under the SPP will rank equally with existing Shares.

Eligible Shareholders

Participation in the SPP is optional and open to eligible shareholders who are registered holders of Shares on the Record Date (being 7.00pm (AEST) on 1 May 2026 with a registered address on the register in Australia or New Zealand) (**Eligible Shareholders**). Certain Eligible Shareholders who are custodians holding Shares on behalf of certain beneficiaries are also invited to participate in the SPP on the terms and conditions set out in the Prospectus.

Shareholders in the United States are not eligible to participate in the SPP. Similarly, Shareholders (including trustees, custodians and nominees) who hold Shares on behalf of persons in the United States or are acting for the account or benefit of persons in the United States, are not eligible to participate in the SPP on behalf of those persons.

IPD will not issue SPP Shares to an applicant if those Shares, either alone or in conjunction with the issue of Shares under other applications received by IPD, would contravene any law or the ASX Listing Rules.

Important information regarding potential scale-back in the SPP

IPD is targeting to raise up to approximately \$2.0 million under the SPP Offer. However, IPD may decide to accept applications (in whole or in part) that result in the SPP Offer raising more or less than that target amount at its absolute discretion.

If the Company receives oversubscriptions above 200 million SPP Shares under the SPP Offer, it may (in its discretion) scale back each Applicant's allocation on a pro rata basis (with reference to each shareholder's holding on the Record Date). If the Company accepts oversubscriptions above 200 million under the SPP Offer and needs to scale back such oversubscriptions, it will scale back each applicable Applicant's allocation on a pro rata basis (with reference to each shareholder's holding on the Record Date).

How to apply

Eligible Shareholders may participate in the SPP by generating their personalised Application Forms and unique BPAY® or EFT numbers by registering online through the Company Registry's website by following the steps outlined in the SPP available online at events.miraqle.com/ipd-spp (you do not need to return an Application Form under this option).

Please note that the final number of SPP Shares to be issued will depend on the final issue price, being \$0.01 per SPP Share or a 2.5% discount to the VWAP of Shares traded on the ASX during the 5 trading days up to the closing date of the SPP.

The SPP is scheduled to close at 5.00pm AEST on Friday, 5 June 2026, by which time we must receive your application and payment.

Key Dates

Event	Dates
Record Date for SPP	7.00pm AEST on Friday 1 May 2026
Announcement of SPP	Monday, 4 May 2026
Prospectus lodgement date with ASX and ASIC	Monday, 4 May 2026
SPP Opening Date	8:00am (AEST) on Tuesday, 12 May 2026
SPP Closing Date	5:00pm (AEST) on Friday, 5 June 2026
Announcement of results of SPP	Wednesday, 10 June 2026
Date of EGM	Thursday, 11 June 2026
Expected date for ASX to grant quotation of SPP Shares issued under SPP Offer	Monday, 15 June 2026
Issue of Shares under SPP and commencement of trading	Monday, 15 June 2026

These dates are indicative and subject to change without notice to you. All references to a time are in Australian Eastern Standard Time (AEST).

Important Information

The SPP is governed by the Prospectus (available at events.miraqle.com/ipd-spp). I encourage you to read this Prospectus carefully and in its entirety before making a decision on whether to participate in the SPP Offer.

You should be aware that the future market price of the Shares is uncertain and may rise or fall. This means the price you pay for Shares under the SPP Offer may be either higher or lower than the Share price trading on the ASX at the time Shares are issued to you under the SPP Offer.


If you are uncertain whether the Shares under the SPP Offer are a suitable investment for you, please consult your financial or other professional adviser. The Board recommends that you obtain your own financial advice in relation to the SPP Offer and consider price movements of the Company's Shares prior to electing to participate in the SPP Offer.

Capitalised terms used in this document have the same meaning as given to those terms in the Prospectus, unless the context otherwise requires.

Further Questions

Shareholders who have any questions regarding the SPP Offer should call MUFG Corporate Market on **1300 853 481 (within Australia)** or **+61 1300 853 481 (outside Australia)** between 8:30am and 5:00pm (AEST), Monday to Friday (excluding public holidays).

Yours faithfully



Christine Emmanuel-Donnelly
Chair

For personal use only
SAMPLE

12 May 2026

Share Purchase Plan Letter to Ineligible Shareholders

Dear Shareholder

Information Regarding Your Eligibility under the Share Purchase Plan

On 4 May 2026, ImpediMed Limited (ASX: IPD) (**ImpediMed** or the **Company**) announced the opportunity for shareholders to participate in a Share Purchase Plan (**SPP**) by applying for up to \$100,000 worth of new ordinary shares in the Company (**SPP Shares**), at a price which is equal to the lower of \$0.01 per SPP Share or 2.5% discount to the VWAP of the Company's shares traded on the ASX during the 5 trading days up to the closing date of the SPP (**Issue Price**) to raise up to approximately \$2.0 million.

Each Eligible Shareholder will also receive one Attaching Option (exercise price of \$0.01 and expiry date of 31 March 2027) and one Follow-On Option (exercise price of \$0.015 and expiry date of 31 December 2027) for every SPP Share subscribed.

The Company reserves the right to accept oversubscriptions up to a total of 100 million additional SPP Shares under the SPP.

This letter is to inform you that according to our records, under the terms of the SPP described below, you are an ineligible shareholder and therefore not eligible to subscribe for SPP Shares. Accordingly, the Company is not extending the SPP to you and this letter does not constitute an offer or an invitation to apply for SPP Shares under the Prospectus.

About the Placement and SPP Offer

The SPP is part of a broader capital raising being undertaken by ImpediMed. As announced to ASX on 4 May 2026, the Company is undertaking a placement and the SPP to raise a total of approximately \$15.2 million in order to strengthen its balance sheet by partially prepaying the SWK Facility and providing additional working capital to support its ongoing operations.

The first tranche of the placement has raised \$3.0 million (before costs). Completion of the second tranche and the SPP are each conditional on shareholder approval, which will be sought at an extraordinary general meeting scheduled on 11 June 2026 (**EGM**).

If Shareholders do not approve either the issue of securities under the second tranche of the placement or the issue of securities under the SPP, tranche 2 of the placement and the SPP will not proceed, and the Company will not raise any further funds.

The SPP is being made pursuant to a prospectus dated 4 May 2026 issued in accordance with Section 713 of the Corporations Act (**Prospectus**). A copy of the above announcement, together with further details of the SPP, is available on the Company's website at <https://www.impedimed.com/> and also on the ASX Announcement Platform. A copy of the Prospectus has been lodged with the Australian Securities and Investments Commission (**ASIC**) and the ASX and is available for viewing on the ASIC, ASX and Company's website.

Eligibility

Participation in the SPP is optional and is open to eligible shareholders who are registered holders of Shares on the Record Date (being 7.00pm (AEST) on 1 May 2026 with a registered address on the register in Australia or New Zealand) (**Eligible Shareholders**).

These eligibility restrictions arise from legal and regulatory requirements in countries other than Australia and New Zealand, as well as the potential costs to the Company of complying with these requirements.

You are not required to do anything in response to this letter.

Further information

For further information on the SPP Offer, or if you believe you may be an Eligible Shareholder, please call MUFG Corporate Market on **1300 853 481 (within Australia)** or **+61 1300 853 481 (outside Australia)** between 8:30am and 5:00pm (AEST), Monday to Friday (excluding public holidays).

If you have any further questions, you should contact your stockbroker, solicitor, accountant or other professional advisor. On behalf of the board, I look forward to your continued support.

Yours faithfully



Christine Emmanuel-Donnelly
Chair